Table 1 Participant-reported functioning and symptom measures in 13 participants with breast cancer who were surveyed at the time of sample submission.
Questionnaire scores, median (IQR) | |
|---|---|
EORTC core quality of life questionnaire (QLQ C-30) | |
Functioning | |
Overall wellbeing | 75 (67–83) |
Physical functioning | 93 (93–100) |
Role functioning | 100 (83–100) |
Ability to work | 1 (1–2) |
Emotional functioning | 67 (67–92) |
Cognitive functioning | 83 (83–100) |
Social functioning | 83 (67–100) |
Financial impact | 0 (0–0) |
Symptoms | |
Worry | 2 (1–3) |
Depressed | 2 (1–2) |
Pain | 17 (0–33) |
Fatigue | 33 (22–33) |
Insomnia | 33 (33–67) |
Nausea and vomiting | 0 (0–0) |
Dyspnea | 33 (0–33) |
Appetite loss | 0 (0–0) |
Constipation | 0 (0–33) |
Diarrhea | 0 (0–67) |
EORTC breast cancer-specific quality of life questionnaire (QLQ-BR23) | |
Functioning | |
Sexual functioning | 17 (0–33) |
Body image | 67 (33–67) |
Symptoms | |
Arm symptoms | 11 (0–22) |
Hot flushes | 4 (3–4) |
EORTC quality of life questionnaire liver module (QLQ-LMC21) | |
Symptoms | |
Peripheral neuropathy | 33 (33–67) |
Functional assessment of cancer therapy endocrine subscale (FACT-ES) | |
Symptoms | |
Vaginal symptoms | 50 (38–57) |
Arthralgia | 2 (1–2) |
Measures of satisfaction with breast | |
BREAST-Q mastectomy | 53 (48.5–62) |
BREAST-Q breast conserving Therapy | 68 (59.5–97) |
